Interpretation of the ASCO practice guideline:Chemotherapy and targeted for women with HER2-Negative (or unknown) advanced breast cancer
GAO Guo-xuan
LIU Yin-hua
Abstract：In October 2014 Journal of Clinical Oncology,it published the Chemotherapy and Targeted for Women With Human Epidermal Growth Factor Receptor 2-Negative (or unknown) Advanced Breast Cancer:ASCO Practice Guideline. Recommendations include:Endocrine therapy is preferable to chemotherapy as first-line treatment for patients with estrogen receptor-positive metastatic breast cancer unless improvement is medically necessary (eg, immediately life-threatening disease).Single agent is preferable to combination chemotherapy,and longer planned duration improves outcome but must be balanced against toxicity.There is no single optimal first-line or subsequent line chemotherapy,and choice of treatment will be determined by multiple factors including prior therapy,toxicity,performance status,comorbid conditions,and patient preference.The role of bevacizumab remains controversial.Other targeted therapies have not so far been shown to enhance chemotherapy outcome in HER2-negative breast cancer.
Keywords：advanced breast cancerHER2-negative
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 27-29 )